Optimi Health Completes First Psilocybin Export to UK for Phase 2 Clinical Trial
OPTH sits 57% above its 52-week low of $3.
Summary
Optimi Health has completed its first export of naturally derived psilocybin, including biomass and 5mg capsules, to the United Kingdom. This shipment supports a planned Phase 2 clinical trial in the UK, expanding the company's international reach beyond its existing supply to Australia and Canada. This follows the company's recent completion of a GMP production run of 5mg psilocybin capsules and a CAD$18.4 million Nasdaq public offering. The export validates Optimi's GMP manufacturing and regulatory capabilities for international clinical research, positioning it as a vertically integrated supplier in the psychedelic medicine space. The company intends to announce the trial partner and specific indication at a later date.
At the time of this announcement, OPTH was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.7M. The 52-week trading range was $3.00 to $8.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.